Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Climb Bio, Inc. Director's Dealing 2021

Aug 10, 2021

33982_dirs_2021-08-09_7bceecae-24ee-46ed-950e-a49462f67396.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2021-08-09

Reporting Person: RA CAPITAL MANAGEMENT, L.P. (Director, 10% Owner)
Reporting Person: RA Capital Healthcare Fund LP (Director, 10% Owner)
Reporting Person: RA Capital Nexus Fund, L.P. (Director, 10% Owner)
Reporting Person: RA Capital Nexus Fund II, L.P. (Director, 10% Owner)
Reporting Person: Kolchinsky Peter (Director, 10% Owner)
Reporting Person: Shah Rajeev M. (Director, 10% Owner)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 2867219 Indirect
Common Stock 216113 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series A Preferred Stock $ Common Stock (2639507) Indirect
Series A-1 Preferred Stock $ Common Stock (1415002) Indirect
Series B Preferred Stock $ Common Stock (673076) Indirect
Series A Preferred Stock $ Common Stock (708333) Indirect
Series A-1 Preferred Stock $ Common Stock (518164) Indirect
Series B Preferred Stock $ Common Stock (288461) Indirect
Series A Preferred Stock $ Common Stock (485493) Indirect
Series A-1 Preferred Stock $ Common Stock (139481) Indirect

Footnotes

F1: Each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") is convertible at the option of the holder and will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Preferred Stock has no expiration date.

F2: Shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F4: Shares held directly by the Nexus Fund.

F5: Shares held directly by the Nexus Fund II.

F6: Shares held directly by the Account.